Genetic Technologies Limited
GENE
$2.25
$0.03161.42%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.29M | 1.30M | 1.51M | 1.55M | 1.37M |
| Total Other Revenue | 297.90K | 299.40K | 279.80K | 286.30K | 270.90K |
| Total Revenue | 1.59M | 1.60M | 1.79M | 1.84M | 1.64M |
| Cost of Revenue | 572.30K | 575.10K | 730.60K | 747.60K | 706.20K |
| Gross Profit | 1.02M | 1.02M | 1.06M | 1.09M | 930.70K |
| SG&A Expenses | 1.89M | 1.90M | 1.75M | 1.79M | 1.83M |
| Depreciation & Amortization | 91.50K | 91.90K | 115.70K | 118.40K | 108.60K |
| Other Operating Expenses | 591.50K | 594.40K | 631.70K | 646.30K | 586.10K |
| Total Operating Expenses | 3.27M | 3.29M | 3.47M | 3.55M | 3.41M |
| Operating Income | -1.68M | -1.69M | -1.68M | -1.72M | -1.77M |
| Income Before Tax | -2.09M | -2.10M | -2.10M | -2.15M | -1.84M |
| Income Tax Expenses | -- | -- | -3.40K | -3.50K | -48.70K |
| Earnings from Continuing Operations | -2.09M | -2.10M | -2.10M | -2.15M | -1.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.09M | -2.10M | -2.10M | -2.15M | -1.80M |
| EBIT | -1.68M | -1.69M | -1.68M | -1.72M | -1.77M |
| EBITDA | -1.59M | -1.60M | -1.66M | -1.70M | -1.66M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 115.42M | 115.42M | 110.42M | 110.42M | 92.34M |
| Average Diluted Shares Outstanding | 115.42M | 115.42M | 110.42M | 110.42M | 92.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
